Acute kidney injury
Conditions
Interventions
Experimental Group:Gene polymorphism monitoring
Experimental Group:Population pharmacokinetic technology to design individualized dosing regimens
Experimental Group:Standardized monitoring of vancomycin blood concentration
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Inpatients planning to receive intravenous vancomycin in key departments (respiratory department, respiratory care unit, surgical intensive care unit, etc.) from June 2022 to May 2023; 3. Patients who signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients receiving renal replacement therapy (regular hemodialysis, peritoneal dialysis, etc.) or chronic renal insufficiency grade 5; 2. The patient underwent nephrectomy during hospitalization; 3. Patients with severe systemic concurrent diseases (systemic multiple organ failure, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence rate of acute kidney injury; | — |
Secondary
| Measure | Time frame |
|---|---|
| renal outcomes;Clinical efficacy indicators;Bacteriological efficacy; | — |
Countries
China
Contacts
Public ContactYing Zhou
Department of Pharmacy, Peking University First Hospital
Outcome results
None listed